Document LKLmgXeaO2KJkOQZJxDJ071pX

) The Cosmetic Toiletry and Fragrance Association Inc. 1133 15th STREET N.W. WASHINGTON D.C. 20005 331-1770 TELEX 89-2673 James H. Merritt President . Norman F. Estrin Ph.D. Vice President MINUTES E. Edward Kavanaugh Vice President- Congressional Relations Margaret W. Smith Executive Secretary CTFA TECHNICAL ADMINISTRATION COMMITTEE A meeting of CTFA Technical Administration Committee was held on February 1 1977 at the Old Towne Holiday Inn in Alexandria Virginia Members of the Committee present were Robert Giovacchini The Gillette Company Murray Berdick Chesebrough Inc. Eustace Fotiu Revlon Inc. ; Yale Gressel Avon Products Inc. John Menkart Clairol Inc. ; James Rodgers The Mennen Company Guest Charles Rowland Avon Products Inc. Maurice Siegel Faberge Inc. Norman Estrin CTFA James Merritt CTFA James McNerney CTFA In addition the following guests from the FDA were James Akers n Henry Davis Heinz Eiermann Hyman Gittes Sidney Green Martin Greif A.C. Kolbye John Lucas Frank Marzulli Robert Schaffner Robert Scheuplein John Wenninger Dr. Giovacchini opened the meeting and had the participants introduce themselves Giovacchini in his opening remarks stressed the importance on scientific issues to in maintaining promote mutual a dialogue among scientists respect for points of view He then proceeded with the agenda Protected Document to Protective order JNJ 000026623 ; a oe . Y @ . 4 prepared explaining to consumers the state of research | Dr. Menkart agreed this the matter further It area must continue was was a good agreed suggestion and will study the dialogue in this 4 Talc -- Dr. Estrin reported publication of a new CTFA Standard for talc and distributed copies to FDA He described a robin test of cosmetic talcs which have been recently purchased on the open market Participants in the robin test include scientists from Mt. Sinai Hospital and the Food and Drug Administration Mr. Henry Davis reported on FDA's work on methodology and described the comparison between the CTFA method and FDA's method as follows CTFA FDA 1. Analysis 2. Sensitivity 3. Tremolite Standard 4. Slits Qualitative 0.5 | . CTFA Quantitative 0.1 Korean A. Divergence B. Receiving 5. Mixing 6. Equipment 1 0.2mm Spex Mixer Mill : , 0..5 0.3mm Manual Phillips Electronic 3500 Dr. Estrin noted that FDA had been invited to participate at meetings CTFA has with the Mt. Sinai group and noted the desirabilitoyf FDA participation in the future Dr. Marzulli reported on papers showing cancer from glass fibers and suggested that possibly shape was more important than the type of particle Dr. Giovacchini responded the work referred to was not new in the scientific literature Mr. Wenninger updated the Committee briefly on the National Bureau of Standards work on talc exposures 5 Aerosols -- Dr. Gressel described the propellant program undertaken by the Industry Aerosol Safety Committee and current work by a Hydrocarbon Subcommittee which is combining Protected Document to Protective order JNJ 000026624